Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA-11 PET/CT in biochemical recurrent prostate cancer
NCT05847348Phase 3Recruiting
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 3 trial of TLX007-CDx in prostate cancer (PCa), sponsored by Telix Pharmaceuticals Limited. Started Jul 2023; status: recruiting.
02
Drugs
TLX007-CDx
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05847348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05847348.